Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Correlation Between Visual Reading and DOlab Software Quantitative Analysis of DaT-SPECT Images

11 november 2026 bijgewerkt door: Dorian Technologies S.r.l.

Pre-market Clinical Investigation to Evaluate the Correlation Between Visual Interpretation and Quantitative Analysis Performed by DOlab Software - DaT-SPECT Workflow for the Identification of Neurological Disorders Related to Dopamine Transporter Dysfunction

The goal of this study is to find out whether the quantitative results of DOlab software (DaT-SPECT workflow) agree with the visual reading of brain scans performed by nuclear medicine physicians. The scans are 123I-ioflupane DaT-SPECT images of adults who were evaluated for dopamine transporter dysfunction, a condition seen in Parkinson's disease, other parkinsonian syndromes and dementia with Lewy bodies.

The main questions it aims to answer are:

  • Do the visual scores given by expert readers (0 = normal to 3 = marked abnormality) correlate with the values calculated by the software?
  • Does using the software report change or refine the readers' classification compared with visual reading alone?
  • How usable do readers find the software?

The study uses existing scans of 120 patients collected between January 2015 and May 2025 at two Italian hospitals. No new tests or treatments are given to participants, and the software results are not used for their clinical care.

Studie Overzicht

Gedetailleerde beschrijving

Dopamine transporter (DaT) SPECT with 123I-ioflupane is widely used to support the diagnosis of neurological disorders associated with nigrostriatal dopaminergic degeneration. Visual reading by trained physicians is the clinical standard, and semi-quantitative analysis is recommended by the EANM/SNMMI guidelines as an objective complement, especially in borderline cases.

DOlab software - DaT-SPECT workflow (Dorian Technologies; investigational, not CE-marked, class IIa) iteratively maps each scan to MNI space with adaptive volumes of interest for the right and left caudate, anterior putamen and posterior putamen, plus an occipital reference region. It computes four metrics: striatal binding ratio (SBR), Southampton SBR, Basal Ganglia V3 and Volume Fraction. The results are compared with a normative database derived from the Parkinson's Progression Markers Initiative (PPMI) and reported as z-scores.

This is a blinded, multicenter, retrospective investigation at two Italian sites. At each site, an independent reader selects 15 consecutive scans for each visual grade (0, 1, 2, 3), for a total of 120 scans. The images are pseudonymized and uploaded to a shared repository.

Phase 1: four independent readers (two per site), blinded to all clinical information except sex and age, visually score the randomized images (0-3) for the caudate, anterior putamen and posterior putamen of each hemisphere. In parallel, the software analyzes the same images, and the visual scores are correlated with the software metrics.

Phase 2: the images are re-randomized and re-coded, and the same readers perform a semi-quantitative assessment supported by the software report. Classifications from the two phases are then compared. Finally, the readers complete the System Usability Scale (SUS).

Sample size: 85 subjects are needed to detect a correlation of 0.30 (two-sided alpha 0.05, power 80%). 120 subjects are planned to allow for non-evaluable images.

Studietype

Observationeel

Inschrijving (Geschat)

120

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Tuscany
      • Prato, Tuscany, Italië, 59100
        • Werving
        • Azienda USL Toscana Centro - Ospedale Santo Stefano
        • Hoofdonderzoeker:
          • Stelvio Sestini, MD
    • Veneto
      • Padova, Veneto, Italië, 35128
        • Werving
        • Azienda Ospedale Università Padova
        • Hoofdonderzoeker:
          • Diego Cecchin, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Adults referred for evaluation of nigrostriatal dopaminergic dysfunction who underwent 123I-ioflupane DaT-SPECT between January 2015 and May 2025 at Santo Stefano Hospital (Prato) or the University Hospital of Padua, Italy. At each center, 15 consecutive scans per visual grade (negative, mild, moderate and marked abnormality) are selected retrospectively.

Beschrijving

Inclusion Criteria:

  • Age 18 years or older.
  • Referred for evaluation of nigrostriatal dopaminergic dysfunction to one of the participating centers between January 2015 and May 2025.
  • Informed consent for data collection, or documentation that all reasonable efforts to obtain consent were made (Italian Privacy Code, art. 110).
  • 123I-ioflupane SPECT images that:
  • were acquired according to the PPMI imaging protocol;
  • have a field of view covering the entire head, from the superior cortical regions to the lower cerebellum;
  • followed the radiotracer manufacturer's acquisition timing and methods;
  • were attenuation-corrected according to local standard procedures.

Exclusion Criteria:

  • Age under 18 years.
  • Use of drugs or substances that may significantly affect DaT binding (e.g., cocaine, amphetamines, CNS stimulants, opioid derivatives, antidepressants, adrenergic agonists, anticholinergics, anesthetics) without a washout of at least five biological half-lives before DaT-SPECT, per the EANM/SNMMI guidelines.
  • DaT-SPECT performed outside the January 2015 - May 2025 period.
  • Images not meeting the acquisition and quality specifications listed above.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: CASE_ONLY
  • Tijdsperspectieven: RETROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Adults referred for DaT-SPECT

Adults referred for evaluation of nigrostriatal dopaminergic dysfunction at the two participating centers between January 2015 and May 2025, whose existing 123I-ioflupane DaT-SPECT scans were selected retrospectively (30 per visual grade 0-3, 15 per grade per center). Each scan is read visually by four blinded readers, analyzed by DOlab software, and then re-read with the software report.

Investigational software (not CE-marked, class IIa) that automatically quantifies striatal 123I-ioflupane binding using four metrics (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) and compares them with a PPMI-based normative database. It is applied retrospectively to existing images, and its output is not used for patient care.

Visual reading of the same 123I-ioflupane images by blinded nuclear medicine physicians, scored 0-3 for the caudate, anterior putamen and posterior putamen of each hemisphere, according to the EANM/SNMMI guidelines.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Correlation between visual score and DOlab quantitative metrics
Tijdsspanne: Phase 1 reading session, within 4 months of study start

Pearson correlation coefficient (with 95% CI) between the readers' visual score (ordinal 0-3; 0 = normal, 3 = marked abnormality) and each continuous metric produced by DOlab software (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) for the caudate, anterior putamen and posterior putamen of each hemisphere. If the Pearson assumptions are not met, the Spearman rank correlation is reported.

Phase 1 reading session, within 4 months of study start

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Agreement between visual and software-supported semi-quantitative classification
Tijdsspanne: Phase 2 reading session, within 4 months of study start

Cohen's kappa coefficient between the classifications given by the same readers with visual reading alone (Phase 1) and with the DOlab software report (Phase 2).

Phase 2 reading session, within 4 months of study start
Number of scans reclassified with software support
Tijdsspanne: Phase 2 reading session, within 4 months of study start

Number and percentage of scans whose classification changes between visual reading alone and software-supported reading (e.g., borderline to abnormal), tested with McNemar's test for paired proportions.

Phase 2 reading session, within 4 months of study start
Software usability (System Usability Scale)
Tijdsspanne: After the Phase 2 reading session, within 4 months of study start

SUS questionnaire completed by the 4 readers: 10 items on a 5-point scale. SUS total score from 0 to 100, where higher scores indicate better perceived usability; item responses are also reported as median and IQR.

After the Phase 2 reading session, within 4 months of study start

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Stelvio Sestini, MD, Azienda USL Toscana Centro - Santo Stefano Hospital, Prato

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

13 oktober 2026

Primaire voltooiing (Geschat)

1 januari 2027

Studie voltooiing (Geschat)

1 maart 2027

Studieregistratiedata

Eerst ingediend

11 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 november 2026

Eerst geplaatst (Werkelijk)

17 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

11 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data and images will not be shared, because the clinical investigation plan restricts data use to the sponsor and investigators and the dataset includes pseudonymized imaging data of patients who could not all be reconsented. Aggregate results will be published.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren